The global scleroderma therapeutics market size was valued at USD 1.60 billion in 2018 and is estimated to expand at a CAGR of 6.0% from 2019 to 2026. The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis. Lack of curative therapies and high prevalence of off-label drug use are underlying factors spurring interest in rare disease markets. The emergence of first-in-class curatives that are currently undergoing clinical development will also boost market growth over the forecast period. Furthermore, supplemental approvals for existing treatment options will reinforce growth. Based on indication, the scleroderma therapeutics market is categorized into localized and systemic scleroderma.